Skip to main content

Advertisement

Fig. 2 | Breast Cancer Research

Fig. 2

From: Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers

Fig. 2

Trichostatin A (TSA) and to a lesser extent, 5-aza-2′-deoxycytidine (DAC) treatment induces CREB3L1 mRNA expression. a BT20, HCC1806 and MDA-MB-468 cells were treated with DAC ± TSA. CREB3L1 mRNA levels were quantified (qPCR) relative to a glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific control. Mean ± SD from three independent experiments: *p <0.05; **p <0.01. b CREB3L1 DNA methylation was determined for each sample as for Fig. 1a and plotted with values for the original untreated cell line for comparison. c Parallel samples were treated as in a and cell lysates (50 μg) were immunoblotted for CREB3L1. Additional samples were also treated where indicated with the proteasomal inhibitor MG132 to block CREB3L1 protein degradation. Lysates from MDA-MB-175 cells were included as a positive control for a cell line expressing endogenous CREB3L1. The full-length precursor form (approximately 84 kDa) of CREB3L1 is indicated with arrows; *background band. β-actin levels are shown as loading controls. DMSO dimethyl sulfoxide

Back to article page